Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
about
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonistsComputational approaches in target identification and drug discoveryNeurobiological Insights from mGlu Receptor Allosteric Modulation.Computational methods in drug discoveryEmerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingBiased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsPhasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical NetworkNovel Allosteric Modulators of G Protein-coupled ReceptorsVU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyCurrent and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptorsN-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinAllosteric modulation of metabotropic glutamate receptors.Targeting glutamate synapses in schizophreniaThe clinical implications of mouse models of enhanced anxiety.Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeTargeting metabotropic glutamate receptors for novel treatments of schizophrenia.Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅).Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound.Development of allosteric modulators of GPCRs for treatment of CNS disordersOpportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.Molecular Insights into Metabotropic Glutamate Receptor Allosteric ModulationPositive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders.Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5.CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model.Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesMetabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats.Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.Recent advances in the design and development of novel negative allosteric modulators of mGlu(5)The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophreniaApplication of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4)Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discoveryProgress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).
P2860
Q24632161-F2B03B3D-B1BE-4259-9719-7F884DAE0BACQ26746941-A2309F0A-39DE-4BDC-BA74-33E32E21C9EAQ26773431-650552B6-B24B-4F7C-AA24-854BFEBFA059Q26997089-FACAC4BE-64CD-49E2-8D9F-99C26C8B5671Q27023967-C0A1D98B-6050-44F7-8DB9-3C925BCB127CQ27305419-617D2DE2-A176-4C5C-8CEF-01C147A92889Q27318820-74C54D46-D769-435B-B9A2-86DBE99ADDA2Q28081112-5F04B1BD-96FD-4DBF-8A63-54FAF445D3A1Q30366876-7E2412DC-0D6D-401B-A9EA-7DF1F3E7DC2AQ30382281-B1A70123-925B-47D5-BDD0-3F88D3E53130Q30406728-FC2E03A9-823B-4ED3-A84C-8049894869E4Q30427199-E0820AD0-82AF-4190-8A12-B1F03A396A77Q30427775-BD23D1B3-B396-446F-B610-65F6AD96CE5CQ30448534-E486A037-39F2-4F55-8C9F-AF231614E4D4Q30460392-FD2C7F27-B878-43AE-98C8-9155FDA9D231Q30474232-D0E8FD2E-F1D8-40A2-86B0-4A54B788CAAFQ30535764-88F5E20D-835C-472F-B7ED-51786F2B621DQ30709836-17945CF9-8BEC-4413-941D-13EA886B579AQ30821694-892477EC-25BD-4192-882C-59DD561CEF3BQ33604654-66CDED3B-194D-411D-B7D9-F876657DB307Q33894613-A9D6461E-86DE-457A-8F00-52F10BB7367FQ34135392-C0855812-B951-4C14-A996-A63AB70DCB23Q34373958-B086A09C-3959-49B8-B71A-2D3380731D89Q34399823-B1380F39-EE9C-48D6-94D0-D2E15DF4AEB7Q34451402-A0177CFD-FA0C-407A-8C59-BC9ED2F61FD8Q34468639-9D2047B0-ACD9-4543-B7B0-F6470BA7B404Q34761363-6C100E41-52DE-41D6-A921-2192561938D8Q34850993-A386EC30-D59E-4898-B281-09A3AE242A0AQ34889241-5DC836D2-7948-46AA-99E7-5D9A788F5C51Q34907032-F8FB918C-B142-4DF5-ADAB-D127180FD308Q35065682-E8D36D8E-15D4-420A-86C3-1034ECAC5C45Q35168229-EB8C5625-E77C-47FD-9037-EA64EE71D038Q35188148-D784A732-48B8-4BE2-B5B7-20D5DEF708AAQ35210746-1AF725D8-811A-498B-BACA-FA0C12886A7AQ35222750-41E49C5A-0AFF-49E9-8A6E-E1BCE747A97AQ35602706-265FD5FC-328E-4F22-AFD1-D2490FF6367AQ35614156-CF4094DF-241F-4324-8075-CC052AC46DE3Q35688485-579FDAD0-D51B-4AB6-AFAA-2D11589FC2B8Q35952381-EAF48629-A1E6-4512-A417-D85D4EFAB792Q36015452-1FE71312-148A-4A4C-93DB-6143CC301A45
P2860
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery of novel allosteric ...... ic and antipsychotic activity.
@ast
Discovery of novel allosteric ...... ic and antipsychotic activity.
@en
type
label
Discovery of novel allosteric ...... ic and antipsychotic activity.
@ast
Discovery of novel allosteric ...... ic and antipsychotic activity.
@en
prefLabel
Discovery of novel allosteric ...... ic and antipsychotic activity.
@ast
Discovery of novel allosteric ...... ic and antipsychotic activity.
@en
P2093
P2860
P50
P356
P1476
Discovery of novel allosteric ...... ic and antipsychotic activity.
@en
P2093
Alexander S Kane
Alice L Rodriguez
C David Weaver
Carrie K Jones
Elizabeth J Herman
Emily L Days
Jerri M Rook
Joy E Marlo
Mark D Grier
Paige N Vinson
P2860
P304
P356
10.1124/MOL.110.067207
P577
2010-10-05T00:00:00Z